Nkarta, Inc.
NKTX
Rank in Stocks
#19127
Nkarta, Inc., a clinical-stage biopharmaceutical company, develops and... Nkarta, Inc., a clinical-stage biopharmaceutical company, develops and commercializes natural killer cell therapies for cancer and autoimmune disease treatment. Its lead product candidate is NKX019, a chimeric antigen receptor-natural killer (CAR NK) targeting the CD19 antigen, which is in Phase 1 clinical trial for the treatment of lupus nephritis; systemic sclerosis; idiopathic inflammatory myopathy; and antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis, as well as for systemic lupus erythematosus and myasthenia gravis. The company has a research collaboration agreement with CRISPR Therapeutics AG. Nkarta, Inc. was incorporated in 2015 and is based in South San Francisco, California.
Share Price
$1.59
Last synced: 2026-11-09
Market Cap
$113.88M
Change (1 day)
-8.09%
Change (1 year)
-20.90%
Country
Stock data: Financial Modeling PrepΒ·Updated Β·Not investment adviceΒ·How we calculate this
Trade Nkarta, Inc. (NKTX)
Category
Healthcare
EPS for Nkarta, Inc. (NKTX)
EPS as of September 2026 TTM: $-1.73
According to Nkarta, Inc.'s latest financial reports, its current EPS (TTM) is $-1.73. At the end of 2025 the company had an EPS of $-1.41, an increase over its 2024 EPS of $-1.60.
EPS history for Nkarta, Inc. from 2018 to 2026
EPS at the end of each year
| Year | EPS | Change |
|---|---|---|
| 2026 (TTM) | $-1.73 | 22.70% |
| 2025 | $-1.41 | -11.88% |
| 2024 | $-1.60 | -33.33% |
| 2023 | $-2.40 | -8.05% |
| 2022 | $-2.61 | -0.38% |
| 2021 | $-2.62 | 64.78% |
| 2020 | $-1.59 | -37.65% |
| 2019 | $-2.55 | 46,263.64% |
| 2018 | $-0.01 | 0.00% |
EPS for similar companies or competitors
| Company | EPS | EPS Difference | Country |
|---|---|---|---|
| $15.66 | -1,005.20% |
US
|
|
| $-7.07 | 308.67% |
US
|
|
| $-5.29 | 205.78% |
AU
|
|
| $12.88 | -844.51% |
BE
|
|
| $21.56 | -1,346.24% |
NL
|
Questions about Nkarta, Inc.'s earnings per share (EPS)
What is Nkarta, Inc.'s earnings per share (EPS)?
Nkarta, Inc.'s earnings per share (EPS) over the last twelve months is $-1.73, as of Sep 2026.
What was Nkarta, Inc.'s earnings per share (EPS) in 2025?
In 2025, Nkarta, Inc.'s earnings per share (EPS) was $-1.41, compared with $-1.60 in 2024.
How has Nkarta, Inc.'s earnings per share (EPS) changed since 2020?
From 2020 to 2025, Nkarta, Inc.'s earnings per share (EPS) was highest in 2025 ($-1.41) and lowest in 2021 ($-2.62).
How does Nkarta, Inc.'s earnings per share (EPS) compare with similar companies?
Nkarta, Inc.'s earnings per share (EPS) ($-1.73) is higher than that of 2 of the 5 similar companies listed above. The highest among them is Argenx SE, with $21.56.